Weak Immunogenicity of SARS-CoV-2 Vaccine in Patients with Hematologic Malignancies

0
11
The authors evaluated the safety and immunogenicity of BNT162b2 vaccine in patients with hematological malignancies.
[Blood Cancer Journal]
Full Article